Increasingly biopharmaceutical manufacturers must continuously be looking forward and challenging their assumptions throughout the clinical development process as rapid innovation and evolving access dynamics are changing the commercialization model in ways no one could have expected and will continue to do so for the foreseeable future.
John Jaeger, a Partner leading DRG Consulting’s Life Sciences Practice, is a commercial strategy consultant with a strong track record of client service and US pricing, reimbursement, and market access expertise. In particular, John has a strong interest and focus in partnering with clients on the development and implementation of innovative segment based engagement, successful market entry, and post-launch optimization.
For over 10 years, John has worked across the US healthcare landscape on a variety of topics including healthcare reform, product launch, portfolio and life-cycle management, pricing and contract strategy, and regional influence mapping. As part of DRG Consulting, John has supported a wide range of clients from top 10 pharma manufacturers to pre-clinical start-ups.
Outside of DRG Consulting, John has presented at multiple leading industry conferences, including MassBIO, Pharmaceutical Marketing Research Group, Biosimilars Advisory Service, and the Managed Markets Summit regarding biosimilar commercial strategy and evolving benefit design structures. Mr. Jaeger is an adjunct professor for the University of Sciences MBA program and is a guest lecturer for the Rutgers MBA program.
John completed a MPA in Public Health at the University of Delaware, where he was a fellow in the Center for Applied Demography and Survey Research. His graduate-level research focused on Delaware Medicaid and the impact of the program on indigent health within the Delmarva region. John also holds a BS in Public Administration from Shippensburg University.